4.7 Article

Increased Risk of Incident Diabetes Among Individuals With Latent Tuberculosis Infection

Journal

DIABETES CARE
Volume 45, Issue 4, Pages 880-887

Publisher

AMER DIABETES ASSOC
DOI: 10.2337/dc21-1687

Keywords

-

Funding

  1. National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health [R01AI153152, R03AI133172]
  2. NIAID [K24AI114444, U19AI111211, P30AI051519]
  3. VA awards CSP [I01 CX001899, I01 CX001737]
  4. National Institutes of Health [R21DK099716, R18DK066204, R21AI156161]
  5. Cystic Fibrosis Foundation [PHILLI12A0]

Ask authors/readers for more resources

The study used longitudinal data to show that LTBI is associated with increased diabetes incidence. Even after adjusting for covariates, the diabetes incidence rate remained higher in patients with LTBI. Among patients with LTBI, the diabetes incidence rate was similar in those treated for LTBI compared with those who were not treated.
OBJECTIVE In cross-sectional U.S. studies, patients with diabetes had twice the prevalence of latent tuberculosis infection (LTBI) compared with those without diabetes. However, whether LTBI contributes to diabetes risk is unknown. We used longitudinal data to determine if LTBI is associated with increased diabetes incidence. RESEARCH DESIGN AND METHODS We conducted a retrospective cohort study among U.S. Veterans receiving care in the Veterans Health Administration from 2000 to 2015. Eligibility included all patients without preexisting diabetes who received a tuberculin skin test (TST) or interferon-gamma release assay (IGRA). We excluded patients with a history of active TB and those diagnosed with diabetes before or within 2 years after LTBI testing. Patients were followed until diabetes diagnosis, death, or 2015. LTBI was defined as TST or IGRA positive. Incident diabetes was defined by use of ICD-9 codes in combination with a diabetes drug prescription. RESULTS Among 574,113 eligible patients, 5.3% received both TST/IGRA, 79.1% received TST only, and 15.6% received IGRA only. Overall, 6.6% had LTBI, and there were 2,535,149 person-years (PY) of follow-up after LTBI testing (median 3.2 years). The diabetes incidence rate (per 100,000 PY) was greater in patients with LTBI compared with those without (1,012 vs. 744; hazard ratio [HR] 1.4 [95% CI 1.3-1.4]). Increased diabetes incidence persisted after adjustment for covariates (adjusted HR [aHR] 1.2 [95% CI 1.2-1.3]) compared with those without LTBI. Among patients with LTBI, diabetes incidence was similar in those treated for LTBI compared with those who were not treated (aHR 1.0 [95% CI 0.9-1.1]). CONCLUSIONS Comprehensive longitudinal data indicate that LTBI is associated with increased diabetes incidence. These results have implications for people with LTBI, similar to 25% of the global population.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available